AstraZeneca said on Tuesday that it has requested an emergency use authorization (EUA) grant from the US Food and Drug Administration for its COVID-19 prophylaxis drug, a move that will take a month after the antibody cocktail was effective in preventing symptoms. comes later. High-risk individuals who received the drug prior to exposure.
AstraZeneca said the antibody therapy, called AZD7442, was 77% effective in reducing the risk of developing COVID-19 symptoms in people who received the drug as a preventive measure. Press releaseCiting its third stage mark featuring more than 5,000 participants.
According to the drug manufacturer, the antibody cocktail can be used to protect people who cannot develop a strong immune response to COVID-19 vaccines.
Unlike a vaccine that helps a recipient’s immune system to manufacture its own antibodies and infection-fighting cells against the virus, antibody treatments directly use laboratory-produced antibodies that remain in a person for months. and protect them from infection.
The company also noted that the ‘in vitro’ (in test tube) tests showed that the drug was able to neutralize emerging COVID variants including delta and mu.
The drugmaker said supply agreements for AZD7442 are ongoing with other governments in the United States and around the world.
This is a developing story.